In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

Symptom screening improved symptom scores among children with cancer compared with usual care, two randomized trials showed.

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...